



# 6.60% p.a. EUR Barrier Reverse Convertible

Linked to UBI BANCA SPA

Issued by UBS AG, London Branch



Cash settled; Domestic Style; Kick In Observation at Expiry

EUSIPA Product Type: Barrier Reverse Convertible (1230)

ISIN: DE000UY5MCR9 Valor: 48169352 WKN: UY5MCR

Public Offering

Final Termsheet

## Description of the Product

### Information on Underlying

Underlying	Reference Level	Strike Level	Barrier Level	Multiplication Factor
<b>UBI BANCA SPA</b> Bloomberg: UBI IM Equity ISIN: IT0003487029 RIC: UBI.MI	2.31 (Official closing price of the Underlying on the Fixing Date)	2.31 (100% of the Reference Level)	1.6170 (70% of the Reference Level)	43.290043 (NA/Strike Level)

### Product Details

Security Numbers	ISIN: DE000UY5MCR9 Valor: 48169352 WKN: UY5MCR Common Code: 201675855
Issue Size	100,000 Units (with reopening clause)
Denomination / Nominal Amount	EUR 100
Issue Price	EUR 100 per unit (unit quotation)
Redemption Currency	EUR
Interest Payment	6.60% p.a., payable at the Interest Payment Dates
Quoting Type	Secondary market prices are quoted in units and dirty; accrued Coupon Amount is included in the price.

### Dates

Fixing Date	26-June -2019
Initial Payment Date (Issue Date)	03-July-2019
Last Trading Date / Expiration Date	28-June-2021
Redemption / Maturity Date	05-July-2021 (subject to market disruption event provisions)
Record Date	The Record Date means the day 1 Banking Day(s) before the relevant Interest Payment Date <sub>(i)</sub> .

Interest Payment Date <sub>i</sub>	Interest Payment Dates	Interest Amount
i = 1	02-Aug-2019	0.55%
i = 2	02-Sep-2019	0.55%
i = 3	03-Oct-2019	0.55%
i = 4	04-Nov-2019	0.55%
i = 5	03-Dec-2019	0.55%
i = 6	06-Jan-2020	0.55%
i = 7	03-Feb-2020	0.55%
i = 8	04-Mar-2020	0.55%
i = 9	02-Apr-2020	0.55%
i = 10	05-May-2020	0.55%
i = 11	02-Jun-2020	0.55%
i = 12	03-Jul-2020	0.55%
i = 13	03-Aug-2020	0.55%
i = 14	02-Sep-2020	0.55%
i = 15	05-Oct-2020	0.55%
i = 16	02-Nov-2020	0.55%
i = 17	03-Dec-2020	0.55%
i = 18	05-Jan-2021	0.55%

i = 19	02-Feb-2021	0.55%
i = 20	05-Mar-2021	0.55%
i = 21	06-Apr-2021	0.55%
i = 22	03-May-2021	0.55%
i = 23	02-Jun-2021	0.55%
i = 24	05-Jul-2021	0.55%

## Redemption

The Investor is entitled to receive from the Issuer on the Maturity Date the Redemption Amount, according to the following scenarios

Scenario 1	If the Settlement Price of the <b>Underlying is above the Barrier</b> , the Investor will receive the Nominal Amount in cash.
Scenario 2	If the Settlement Price of the <b>Underlying is at or below the Barrier</b> , the Investor will receive the Settlement Price of the Underlying multiplied with the Multiplication Factor, and if applicable, converted into the Redemption Currency.

The Interest Payment is due in any case.

Settlement Price	The Reference Price of the Underlying on the Expiration Date.
Reference Price	Specified Price per unit of the Underlying, stated in the relevant Currency, and published by the Price Source / Exchange.  Underlying: UBI BANCA SPA (Bloomberg Ticker: UBI IM) Specified Price: official closing price Exchange: Borsa Italiana S.p.A Currency: EUR

## General Information

Issuer	UBS AG, London Branch
Issuer Rating	Aa3 Moody's / A+ S&P's / AA- Fitch
Issuer Supervisory Authority	Swiss Financial Market Supervisory Authority (FINMA). London Branch additionally Financial Conduct Authority (FCA) and Prudential Regulation Authority (PRA). Jersey Branch additionally Jersey Financial Services Commission (JFSC).
Lead Manager	UBS Europe SE
Calculation Agent	UBS AG, London Branch
Paying Agent	UBS AG, London Branch
Relevant Exchange	UBI BANCA SPA: Borsa Italiana S.p.A
Listing	SeDeX
Secondary Market	The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and/or offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and/or offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices.  Daily price indications will be available on Reuters/Bloomberg and <a href="http://www.ubs.com/keyinvest">www.ubs.com/keyinvest</a> .
Trading Hours	09:00 - 17:30
Banking Days	TARGET2
Banking Day Convention	Where any date is used in conjunction with the term "Banking Day Convention", an adjustment will be made if that date would otherwise fall on a day that is not a Banking Day, so that the date will be the first following day that is a Banking Day. Investors shall not be entitled to further interest or other payments in respect of such delay.
Minimum Investment	1 Unit(s)
Minimum Trading Lot	1 Unit(s)
Status	Unsecured / Unsubordinated
Clearing	Euroclear, Clearstream Banking AG, Clearstream Banking S.A. (Global Note at Clearstream Banking AG)
Custody	Clearstream Banking AG eligible (up-to Global Note filed with Clearstream AG, Frankfurt am Main)
Form of Deed	Global Note
Governing Law / Jurisdiction	German / Frankfurt
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed

Public Offering

information on such adjustments is to be found in the Product Documentation.  
Italy

## Product Documentation

---

The complete information regarding the securities, in particular to the terms and conditions as well as information to the Issuer shall be obtained in the respective Final Terms. The respective Final Terms and the associated UBS Base Prospectus along with the Risk Factors (including any supplements thereto) can be ordered free of charge from UBS Europe SE at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main, via +49-(0) 69-1369 8989, fax (+49-(0) 69- 72 22 73) or via e-mail (invest@ubs.com). In addition, the respective documents are available on the internet at <http://www.ubs.com/keyinvest>.

## Important Information

---

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells these securities to dealers and other financial institutions at a discount to the issue price or rebates to them for their own account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the securities (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

## Selling Restrictions

---

**Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.**

**The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.**

### Europe

Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus has not been approved, where necessary passported, and published in accordance with the requirements of the EU-Prospectus Directive, this Product may not be offered or sold in the relevant EEA jurisdictions other than 1) in denominations, or total consideration per investor, of at least EUR 100,000 (or equivalent in other currencies); 2) to any legal entity which is a qualified investors as defined in the EU-Prospectus Directive; 3) to fewer than 150 natural or legal persons (other than qualified investors as defined in the EU-Prospectus Directive) per EEA jurisdiction, or 4) in any other circumstances falling within Article 3 (2) of the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

### Hong Kong

Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

**This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.**

**Singapore**

This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275, of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant of an offer made under Section 275 of the SFA except:
  - (1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA;
  - (2) where no consideration is or will be given for the transfer;
  - (3) where the transfer is by operation of law; or
  - (4) as specified in Section 276 (7) of the SFA.
- (5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

**UK**

For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

**USA**

This Product may not be sold or offered within the United States or to U.S. persons